SCHEMBL1960649

SCHEMBL1960649

CN(C)c1ccc(/C(=C\C2CCCC2)c2cc3cccnc3n2S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38
ALDH1A1 P00352 6/20 0.37
MAPT P10636 4/20 0.37
LMNA P02545 3/20 0.37
CYP2C19 P33261 2/20 0.36
RECQL P46063 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
HTR6 P50406 2/20 0.34
CNR2 P34972 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GAA P10253 1/20 0.33
CYP2C9 P11712 1/20 0.33
APEX1 P27695 1/20 0.33
RAB9A P51151 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1960650 1.00 GCK (0.39) GCKMEN1KMT2ARXFP1ALDH1A1
SCHEMBL1959233 0.90 ALDH1A1 (0.40) GCKKMT2AALDH1A1MAPTLMNA
SCHEMBL1959234 0.90 ALDH1A1 (0.40) GCKKMT2AALDH1A1MAPTLMNA
SCHEMBL1962668 0.88 GCK (0.40) GCKALDH1A1MAPTLMNACYP2C19
SCHEMBL1959817 0.88 GCK (0.40) GCKKMT2AALDH1A1MAPTLMNA
SCHEMBL1962666 0.88 GCK (0.40) GCKALDH1A1MAPTLMNACYP2C19
SCHEMBL1959819 0.88 GCK (0.40) GCKKMT2AALDH1A1MAPTLMNA
SCHEMBL1963220 0.88 GCK (0.38) GCKALDH1A1MAPTLMNACYP2C19
SCHEMBL1963217 0.88 GCK (0.38) GCKALDH1A1MAPTLMNACYP2C19
SCHEMBL1963954 0.87 GCK (0.39) GCKKMT2AALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GCK 1/4885MEN1 2759/4885KMT2A 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.